Posted 26 May 2016

Dr. Sylvain Celanire

Start-up Pitch: PRAGMA Therapeutics

Sylvain Celanire from PRAGMA Therapeutics pitches at The Brain Forum 2016.

About PRAGMA Therapeutics:
PRAGMA Therapeutics is a biotech company developing small molecules acting on the mGlu7 receptor and normalising glutamate dysfunctions, representing an innovative approach for the treatment of Post-Traumatic Stress Disorder (PTSD) and Hearing Loss (such as noise-, age-related hearing loss and tinnitus).
With the support of national and international grants from the French National Research Agency and the Action on Hearing Loss UK charity, PRAGMA discovered first-in-class potent, selective and specific mGlu7 allosteric modulators, and have already demonstrated oral proof-of-concept in preclinical disease models of PTSD.